EHL-FVIII
ApprovedSmall molecule
EHL-FVIII is one of 13 small molecule programs targeting Synovitis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Synovitis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Medrol
PfizerPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
FVIII Concentrate
TThe University of Texas Health Science Center, Houston
Approved
Enbrel
IImmunex
Phase 2
EHL-FVIII
FFederico II University
Approved
MCS110
NovartisPhase 2
Avastin
BBio-Thera Solutions
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EHL-FVIII. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFederico II University